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ABSTRACT
Objective: The aim of this study was to inves-
tigate the influence of cerebrospinal fluid (CSF), 
amyloid β42 (Aβ42), phosphorylated tau181 (p-tau), 
and total tau (t-tau) on cognitive functioning. 
Methods: We analyzed the ability of the 
CSF biomarkers Aβ42, p-tau, and t-tau to pre-
dict the results on the Cambridge Cognitive 
Examination–Revised (CAMCOG-R), a cognitive 
screening test that assesses multiple cognitive 
domains, in 65 memory clinic patients (73.1±8.2 
years) (n=30 probable Alzheimer’s disease [AD], 
n=7 possible AD, n=12 non-AD dementia, n=16 
mild cognitive impairment). 
Results: We found no correlations between 
CSF biomarkers and CAMCOG-R performance 
in the whole group, nor in subgroups based on 
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FOCUS POINTS
•  Cerebrospinal fluid (CSF) Aβ42, p-tau, and 
t-tau do not correlate with cognitive function-
ing in a heterogeneous older population with 
cognitive impairment.
•  Abnormal CSF biomarker concentrations may 
not reflect the absolute amount of neuronal 
damage, but merely serve as an indicator of 
AD pathology.
•  Clinicians should be cautious that CSF bio-
markers cannot be used in isolation to predict 
the severity of cognitive impairment.
aberrant biomarker concentrations. 
Discussion: Changed concentrations of CSF 
amyloid β42, p-tau, and t-tau cannot be directly 
linked to cognitive function in our sample of 
patients with cognitive impairment. Possibly, 
compensatory mechanisms such as cogni-
tive reserve determine cognitive performance, 
rather than the absolute amount of damage 
caused by Aβ deposition and tangle formation. 
In addition, abnormal CSF biomarker concentra-
tions may not be a direct reflection of the amount 
of neuronal damage, but merely serve as an indi-
cator of AD pathology.
Conclusion: While CSF biomarkers are valu-
able in establishing AD pathology, they cannot be 
used to predict severity of cognitive impairment.
CNS Spectr. 2010;15(9):588-593.
INTRODUCTION 
Cerebrospinal fluid (CSF) biomarkers amy-
loid β42 (Aβ42), phosphorylated tau181 (p-tau) 
and total tau (t-tau) concentrations are altered in 
Alzheimer’s disease (AD) patients compared to 
controls. In other types of dementia and also in 
part of the patients with mild cognitive impairment 
(MCI), changes in these biomarker concentrations, 
although less specific, have been reported.1-3 Aβ is 
said to be neurotoxic,4 while CSF tau and p-tau are 
suggested to reflect neurodegeneration.5 Likely, 
pathological concentrations of these proteins 
induce or signal neuronal damage, resulting in 
cognitive impairment. 
 To date, research on the correlation between 
CSF biomarkers and cognitive functions shows 
contradicting results. In AD patients, incon-
sistent correlations between the Mini Mental 
State Examination (MMSE) and Aβ42 have been 
reported.6-9 A correlation between the MMSE and 
tau was often lacking,6,7 but sometimes present.9 
The MMSE is a cognitive screening test that is 
easily applicable in clinical practice, but lacks sen-
sitivity and specificity and may be biased by lack 
of correction for educational level.10,11 This possibly 
explains these inconsistent results. A more exten-
sive assessment of cognitive functioning may be a 
more valid approach to study the relation between 
CSF biomarkers and cognitive functioning. The 
few studies that have used such an extensive 
assessment again showed inconsistent results. In 
AD patients, a weak correlation between a paired-
associate memory test and CSF p-tau and t-tau, 
but not Aβ42, has been reported,12 while others 
failed to find a correlation between the CAMCOG, 
a cognitive measure that covers multiple domains, 
and CSF tau.13 In a heterogeneous group of MCI 
and dementia patients (both AD and non-AD), a 
correlation was found between false recognition 
and levels of CSF Aβ42, but not t-tau.14
We aimed to investigate the influence of CSF 
Aβ42, p-tau, and t-tau concentrations on cognitive 
functioning. We hypothesized that changes in these 
CSF biomarkers reflect neuronal damage and 
directly underlie cognitive impairment. Therefore, 
we expect a correlation between CSF biomark-
ers and cognitive performance, irrespective of the 
clinical diagnosis. To test this hypothesis, we retro-
spectively investigated a heterogeneous group of 
memory clinic outpatients, using the CAMCOG-R 
as a multiple-domain cognitive assessment.
METHODS
This retrospective study used the database 
of the memory clinic of the Radboud University 
Nijmegen Medical Centre/Alzheimer Centre 
Nijmegen. We included all outpatients who visited 
our memory clinic between 2005 and October 2009 
and underwent lumbar puncture as part of their 
diagnostic work up. All patients had a diagnosis 
of either MCI or a type of dementia (note that no 
lumbar punctures have been performed in partici-
pants without impairment on cognitive screening 
tests at admission to the memory clinic). We used 
the Revised Cambridge Cognitive Examination 
(CAMCOG-R) as a measure of cognitive function-
ing.15 Its score ranges from 0–104, with a higher 
score indicating a better performance. Cut-off 
scores adjusted for age and education level have 
been established. Performance can be divided 
into a memory and a non-memory section (maxi-
mum score 37 and 67, respectively). These sections 
have been shown to discriminate between normal 
aging and early AD.16 Time between lumbar punc-
ture and CAMCOG-R had to be <3 months. CSF 
was collected in polypropylene tubes, transported 
at room temperature to the adjacent laboratory 
within 30 minutes, centrifuged after routine inves-
tigations, and immediately aliquoted and stored 
at -80 °C until analysis. Levels of Aβ42, t-tau, and 
p-tau in CSF were measured using enzyme linked 
immunosorbent assays (Innogenetics, Ghent, 
Belgium).
 Sixty-five patients (32 males) were included. 
Of these, 30 were eventually diagnosed with 
probable AD and 7 with possible AD accord-
ing to the National Institute of Neurological and 
Communicative Diseases and Stroke/Alzheimer’s 
Disease and Related Disorders Association 
(NINCDS-ADRDA) criteria,17 16 were diag-
nosed with MCI according to the criteria of the 
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International Working Group on Mild Cognitive 
Impairment,18 and 12 with another type of demen-
tia (5 vascular dementia, 2 frontotemporal demen-
tia, 3 dementia with Lewy bodies, 2 dementia of 
unknown cause) (Table 1). Mean age (±SD) was 
73.1 (±8.2) years.
 We used linear regression to examine the 
relation between CSF biomarkers and the per-
formance on the CAMCOG-R. As dependent vari-
able we used the CAMCOG-R score, related to 
the cut-off value, since this cut-off is adjusted for 
age and education. This relative score was cal-
culated using the following formula: total score/
cut-off x 100, and: (non-)memory score x (cut-
off/maximum score). Aβ42, p-tau, and t-tau con-
centrations were not normally distributed and 
were log-transformed. Analyses were corrected 
for sex. Primary analyses included the total sam-
ple of 65 patients, predicting the CAMCOG-R 
total score and the scores on the memory and 
non-memory sections using CSF biomarkers. 
For secondary analyses, we divided the sample 
into subgroups based on their biomarker results 
to increase the likelihood of a neurodegenera-
tive disorder being present. We used previously 
established cut-off values2 (Table 2) and reran 
our linear regression models. We did not use 
the clinical diagnoses for subgroup analyses, 
since both CAMCOG-R and results of CSF analy-
ses may have influenced the diagnostic decision 
making, whereas CSF biomarker concentrations 
are an objective measure and therefore sub-
group analyses based on these concentrations 
are more likely to yield valid results. 
RESULTS
The Figure shows the correlation between each 
of the CSF biomarkers and the total CAMCOG-R 
score. In the total sample including all 65 patients, 
neither CSF Aβ42, p-tau, t-tau, nor the p-tau/Aβ42 
ratio was a significant predictor of the total score 
on the CAMCOG-R. Using the memory score and 
non-memory score as dependent variables in 
the linear regression model did not change these 
results.
 With respect to the secondary analyses, only 
three models of the 36 models tested showed a 
statistically significant outcome. First, in the group 
with an aberrant Aβ42 concentration, a higher Aβ42 
was related to a higher total CAMCOG-R score (B 
34.8, P=.040). Second, in the group with an aber-
rant p-tau concentration, a higher t-tau was related 
to a lower total CAMCOG-R score (B -24.9, P=.015). 
Last, in the group with an aberrant t-tau concen-
tration, a higher t-tau was related to a lower non-
memory score (B -5.9, P=.046). All other secondary 
analyses (k=33) were not significant (data not 
shown).
DISCUSSION
We investigated the correlation between CSF 
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TABLE 1.
Characteristics of Total Sample and of Subgroups Based on Clinical Diagnosis
Total Sample Probable AD Possible AD Other Types of Dementia MCI
Male/Female 32/33 11/19 4/3 6/6 11/5
Age (years) 73.1±8.2 71.5±8.8 74.3±8.5 76.1±7.5 73.1±7.5
Years of education 10.6±3.8 10.4±3.9 12.0±4.2 11.9±4.3 9.6±2.8
MMSE 21.3±5.2 19.2±3.9 23.6±6.5 19.7±6.2 25.7±2.9
CAMCOG-R total 67.9±15.8 60.5±11.7 73.6±18.4 64.3±18.8 82.0±7.7
CAMCOG-R memory 20.2±6.8 17.0±4.8 22.4±8.4 20.4±7.7 25.2±5.5
CAMCOG-R non-memory 47.7±10.7 43.5±8.9 51.1±11.6 43.8±12.4 56.8±5.2
CSF Aβ42 (pg/ml) 571±225 514±210 506±66 636±232 657±264
CSF t-tau (pg/ml) 570±399 706±464 739±340 334±214 416±250
CSF p-tau181 (pg/ml) 91±47 110±52 110±27 55±30 75±33
Values are expressed as means±SD.
AD=Alzheimer’s disease; MCI=mild cognitive impairment; MMSE=Mini Mental State Examination; CAMCOG-R=Cambridge Cognitive Examination-Revised; 
CSF=cerebrospinal fluid; Aβ42=amyloid β42; t-tau=total tau; p-tau181=phosphorylated tau181.
Spies PE, Claassen JAHR, Slats D, Olde Rikkert MGM, Verbeek MM, Kessels RPC. CNS Spectr. Vol 15, No 9. 2010.
biomarkers and cognitive functioning as measured 
with an extensive cognitive screening instrument 
that covers all major cognitive domains. We did 
not find such a correlation in a heterogeneous 
group of patients with cognitive impairment. 
Secondary analyses in subgroups characterized by 
abnormal biomarker profiles did not convincingly 
change this finding. 
 Our results are in agreement with previous 
research that reported no correlation between the 
CAMCOG and CSF tau in AD patients.13 However, 
we did not replicate previously reported findings 
between CSF biomarkers and memory function.12,14 
Memory function is validly assessed by the mem-
ory section of the CAMCOG-R,16 indicating that a 
correlation, if present, should have been detected 
in our study. Moreover, it is remarkable that previ-
ous studies found correlations in the same cogni-
tive domain but with different CSF biomarkers. 
That is, one found a correlation with p-tau and 
t-tau, but not with Aβ42,12 while another found a 
correlation with Aβ42, but not with tau.14 It is dif-
ficult to explain this discrepancy; it is unlikely that 
this discrepancy can be attributed to differences in 
patient samples—only AD patients, versus a het-
erogeneous group of MCI and dementia patients. 
Furthermore, this cannot explain why we did not 
find a correlation with Aβ42 in our heterogeneous 
group. In addition, a large number of tests and 
analyses have been performed in these previous 
studies that had not been corrected for multiple 
comparisons. The reported correlations were weak 
to moderate at best and in one study possibly 
driven by a cluster of patients with extreme val-
ues of p-tau and t-tau.12 Consequently, it is pos-
sible that these previous findings are the result of 
a Type I error (ie, false positive results).
 We hypothesized that changes in Aβ42 and p-
tau and t-tau, as measured in CSF, would reflect 
neuronal damage leading to impaired cognitive 
functioning. The present findings indicate that 
these changed concentrations in CSF cannot be 
directly linked to cognitive functioning. There are 
several explanations for this. First, it may not only 
be the absolute amount of damage caused by Aβ 
deposition and tangle formation that determines 
cognitive performance, but also compensatory 
mechanisms, such as inter-individual differences 
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TABLE 2.
Characteristics of Subgroups Based on CSF Biomarker Results
Aberrant Aβ42* Aberrant p-tau181* Aberrant t-tau*
All 3 Biomarkers 
Aberrant*
Diagnoses
Probable AD 
Possible AD 
Other dementia 
MCI
19 
3 
4 
7
17 
6 
2 
6
23 
6 
4 
8
13 
3 
1 
4
Male/Female 14/19 16/15 21/20 10/11
Age (years) 71.3±8.0 71.8±8.4 71.7±8.0 70.5±8.8
Years of education 11.3±3.9 10.8±3.9 10.9±3.8 11±3.9
MMSE 20.8±5.5 21.3±6.0 21.2±5.7 20.9±6.1
CAMCOG-R total 65.6±16.4 68.3±17.5 68.2±16.6 67.1±17.6
CAMCOG-R memory 19.5±6.4 20.2±7.0 19.6±7.0 19.7±7.0
CAMCOG-R 
non-memory
46.4±11.5 48.2±11.8 48.6±11.0 47.4±11.9
CSF Aβ42 (pg/ml) 410±73 478±132 515±185 412±70
CSF t-tau (pg/ml) 659±415 881±366 771±374 876±359
CSF p-tau181 (pg/ml) 103±50 131±36 116±42 132±36
*Values are expressed as means±SD. Aberrant Aβ42: <500 pg/ml; aberrant p-tau181: >85 pg/ml; aberrant t-tau: >350 pg/ml.
AD=Alzheimer’s disease; MCI=mild cognitive impairment; MMSE=Mini Mental State Examination; CAMCOG-R=Cambridge Cognitive Examination-Revised; 
CSF=cerebrospinal fluid; Aβ42=amyloid β42; t-tau=total tau; p-tau181=phosphorylated tau181.
Spies PE, Claassen JAHR, Slats D, Olde Rikkert MGM, Verbeek MM, Kessels RPC. CNS Spectr. Vol 15, No 9. 2010.
in cognitive reserve. Plaques and tangles have 
indeed been found in individuals with no signs of 
cognitive impairment during life,19 suggesting that 
these individuals could somehow compensate for 
the neuronal damage induced by the plaques and 
tangles. Moreover, it has been shown that plaque 
burden is a poor correlate of cognitive status at 
the time of death.20
 Alternatively, abnormal CSF biomarker concen-
trations may not be a direct reflection of neuro-
nal damage, but merely serve as an indicator of 
AD pathology. For example, in prodromal AD (ie, 
patients with MCI who developed AD at follow-
up), aberrant concentrations of CSF biomarkers 
have been found.3,21 Furthermore, in patients with 
established dementia, concentrations of CSF bio-
markers remained stable during follow-up, while 
cognitive performance deteriorated.22-24 A correla-
tion between CSF Aβ42 and post-mortem plaque 
burden has been reported to be present25 as well 
as absent.26
 In AD, it has been hypothesized that amyloid 
deposition reaches a plateau before clinical symp-
toms are apparent.5,27 Increased tau is suggested 
to develop later and to continue to increase during 
disease progression.5 According to this model, 
one would not expect a correlation between Aβ42 
and cognitive functioning in AD patients, but one 
would expect a correlation between p-tau and t-tau 
and cognitive functioning in AD patients, regard-
less of causality. To prevent ourselves from merely 
finding a correlation between two features of one 
disease, we examined a heterogeneous group of 
patients with cognitive impairment. We did not 
find a correlation between CSF biomarkers and 
cognitive functioning, showing that CSF biomark-
ers do not directly underlie cognitive impairment 
in a concentration-dependent way. 
CONCLUSION
Concentrations of CSF amyloid β42, p-tau, and 
t-tau have no clear relationship with cognitive 
functioning once cognitive decline has started. 
Severe cognitive impairment can be present in 
the absence of biomarker abnormality, and vice 
versa. Cognitive performance may be determined 
by other factors than the absolute amount of 
damage the brain has suffered, such as cognitive 
reserve. In addition, abnormal CSF biomarker con-
centrations may not reflect the amount of neuro-
nal damage, but merely serve as an indicator of 
Alzheimer’s disease. Clinicians should be cautious 
that CSF biomarkers can be valuable in estab-
lishing AD pathology, but they cannot be used to 
predict severity of cognitive impairment. Future 
studies on the relation between cognitive function 
and CSF biomarkers should focus on the rate of 
cognitive decline over time. CNS  
REFERENCES
 1.    Blennow K. CSF biomarkers for mild cognitive impairment. J Intern Med. 2004;256(3):224-234.
 2.    de Jong D, Kremer BP, Olde Rikkert MG, et al. Current state and future directions of neuro-
chemical biomarkers for Alzheimer’s disease. Clin Chem Lab Med. 2007;45(11):1421-1434.
 3.    Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of 
Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild 
cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 
2009;8(7):619-627.
 4.    Suh YH, Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular 
pathogenesis and pharmacological applications in Alzheimer’s disease. Pharmacol Rev. 
2002;54(3):469-525.
 5.     Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of 
the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119-128.
 6.     Engelborghs S, Maertens K, Vloeberghs E, et al. Neuropsychological and behavioural cor-
relates of CSF biomarkers in dementia. Neurochem Int. 2006;48(4):286-295.
 7.     Ivanoiu A, Sindic CJ. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive 
impairment: prediction of progression to Alzheimer’s disease and correlation with the 
neuropsychological examination. Neurocase. 2005;11(1):32-39.
 8.     Riemenschneider M, Schmolke M, Lautenschlager N, et al. Association of CSF 
apolipoprotein E, Abeta42 and cognition in Alzheimer’s disease. Neurobiol Aging. 
2002;23(2):205-211.
CNS Spectr 15:9 © MBL Communications Inc.      September 2010
Original Research
592
125
100
72
50
25
5.5
4.0 0.0 0.1 0.2 0.3 0.4 0.5 0.65.0 6.0 7.0 8.0
2.5 2.5 2.5 2.5 2.5 2.5 2.56.0 6.5 7.0
CA
M
CO
G-
R 
To
ta
l
125
100
72
50
25
CA
M
CO
G-
R 
To
ta
l
125
100
72
50
25
CA
M
CO
G-
R 
To
ta
l
125
100
72
50
25
CA
M
CO
G-
R 
To
ta
l
Log CSF Aβ42 Log CSF p-tau
Log CSF t-tau p-tau/Aβ42 ratio
*
* ** *
*
*
*
* *
*
*
*
*
*
*
** **
*
*
* *
*
* * *
*
*
**
*
* * * * *
*
* * **
*
*
*
** *
*
****
*
*
*
**
*
**
*
*
Probable AD
Possible AD
Non-AD dementia
MCI
FIGURE.
Scatter plots of CSF biomarkers versus 
total CAMCOG-R score (adjusted for age 
and education) in patients with prob-
able AD, possible AD, non-AD dementia 
and MCI
CSF=cerebrospinal fluid; CAMCOG-R=Cambridge Cognitive Examination-
Revised; AD=Alzheimer’s disease; MCI=mild cognitive impairment; 
MMSE=Mini Mental State Examination;   Aβ42=amyloid β42; t-tau=total tau; 
p-tau181=phosphorylated tau181.
Spies PE, Claassen JAHR, Slats D, Olde Rikkert MGM, Verbeek MM, Kessels 
RPC. CNS Spectr. Vol 15, No 9. 2010.
 9.     Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased 
tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 
2003;289(16):2094-2103.
 10.  Olin JT, Zelinski EM. The 12-month reliability of the Mini-Mental State Examination. Psychol 
Assessment. 1991;3(3):427-432.
 11.  Schmand B, Lindeboom J, Hooijer C, et al. Relation between education and dementia: the 
role of test bias revisited. J Neurol Neurosurg Psychiatry. 1995;59(2):170-174.
 12.  van der Vlies AE, Verwey NA, Bouwman FH, et al. CSF biomarkers in relationship to cogni-
tive profiles in Alzheimer disease. Neurology. 2009;72(12):1056-1061.
 13.  Tsolaki M, Sakka V, Gerasimou G, et al. Correlation of rCBF (SPECT), CSF tau, and cognitive 
function in patients with dementia of the Alzheimer’s type, other types of dementia, and 
control subjects. Am J Alzheimers Dis Other Demen. 2001;16(1):21-31.
 14.  Hildebrandt H, Haldenwanger A, Eling P. False recognition correlates with amyloid-beta (1-
42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive 
impairment. J Alzheimers Dis. 2009;16(1):157-165.
 15.  Roth M, Huppert FA, Mountjoy CQ, et al. The Revised Cambridge Examination for Mental 
Disorders of the Elderly. Cambridge University Press. 1999.
 16.  Schmand B, Walstra G, Lindeboom J, et al. Early detection of Alzheimer’s disease using the 
Cambridge Cognitive Examination (CAMCOG). Psychol Med. 2000;30(3):619-627.
 17.  McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: 
report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and 
Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34(7):939-944.
 18.  Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controver-
sies, towards a consensus: report of the International Working Group on Mild Cognitive 
Impairment. J Intern Med. 2004;256(3):240-246.
 19.  Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med. 
2009;360(22):2302-2309.
 20.  Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer 
disease. J Clin Invest. 2005;115(5):1121-1129.
 21.  Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and MRI biomarkers for 
detecting preclinical Alzheimer’s disease. Psychol Med. 2010;40(1):135-145.
 22.  Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in 
Alzheimer disease: differences between early- and late-onset Alzheimer disease and stabil-
ity during the course of disease. Arch Neurol. 1999;56(6):673-680.
 23.  Sluimer JD, Bouwman FH, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker 
levels in MCI and AD: A longitudinal study. Neurobiol Aging. 2008;
 24.  Zetterberg H, Pedersen M, Lind K, et al. Intra-individual stability of CSF biomarkers for 
Alzheimer’s disease over two years. J Alzheimers Dis. 2007;12(3):255-260.
 25.  Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid-neuropa-
thology in a population-based autopsy study. Neurology. 2003;60(4):652-656.
 26.  Engelborghs S, Sleegers K, Cras P, et al. No association of CSF biomarkers with 
APOEepsilon4, plaque and tangle burden in definite Alzheimer’s disease. Brain. 2007;130(Pt 
9):2320-2326.
 27.  Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive 
synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925-931.
CNS Spectr 15:9 © MBL Communications Inc.      September 2010
Original Research
593
